Evidence map›Paper›PMID 20652728›Full record

ArticlePharmaceutical research2010

Polymethacrylate microparticles gel for topical drug delivery.

Hagar Ibrahim Labouta, Labiba K El-Khordagui

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 12 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Hagar Ibrahim LaboutaDepartment of Pharmaceutics, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt. hagar80im@gmail.com
Labiba K El-Khordagui
Alexandria University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeEvaluating the potentials of particulate delivery systems in topical drug delivery.

methodsPolymethacrylate microparticles (MPs) incorporating verapamil hydrochloride (VRP) as a model hydrophilic drug with potential topical clinical uses, using Eudragit RS100 and Eudragit L100 were prepared for the formulation of a composite topical gel. The effect of initial drug loading, polymer composition, particularly the proportion of Eudragit L100 as an interacting polymer component and the HLB of the dispersing agent on MPs characteristics was investigated. A test MPs formulation was incorporated in gel and evaluated for drug release and human skin permeation.

resultsMPs showed high % incorporation efficiency and % yield. Composition of the hybrid polymer matrix was a main determinant of MPs characteristics, particularly drug release. Factors known to influence drug release such as MPs size and high drug solubility were outweighed by strong VRP-Eudragit L100 interaction. The developed MPs gel showed controlled VRP release and reduced skin retention compared to a free drug gel.

conclusionTopical drug delivery and skin retention could be modulated using particulate delivery systems. From a practical standpoint, the VRP gel developed may offer advantage in a range of dermatological conditions, in response to the growing off-label topical use of VRP.

Indexed as

Acrylic ResinsAdministration, TopicalAdultCalcium Channel BlockersCalorimetry, Differential ScanningDelayed-Action PreparationsDrug CarriersFemaleGelsHumansIn Vitro TechniquesMicroscopy, Electron, ScanningMiddle AgedParticle SizePolymethacrylic AcidsSkinAcrylic ResinsCalcium Channel BlockersDelayed-Action PreparationsDrug CarriersEudragit RSGelsmethylmethacrylate-methacrylic acid copolymerPolymethacrylic AcidsVerapamil

Identifiers

PMID20652728
OpenAlexW2079623339

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.